The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease

被引:0
作者
Lee, Ju Kwang [1 ]
Kim, Seonok [2 ]
Chong, Yong Pil [3 ]
Lee, Hyun Joo [4 ]
Shim, Tae Sun [5 ]
Jo, Kyung-Wook [5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
all-cause mortality; cavitary type; Mycobacterium avium complex; treatment outcome; TREATMENT OUTCOMES; LUNG-DISEASE; TUBERCULOSIS;
D O I
10.1016/j.chest.2024.03.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: The association between treatment outcome and the mortality of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) with cavitary lesions is unclear. This article assessed the impact of culture conversion on mortality in patients with cavitary RESEARCH QUESTION: Is the achievement of sputum culture conversion in patients with MAC-PD with cavitary lesions associated with the prognosis? STUDY DESIGN AND METHODS: From 2002 to 2020, a total of 351 patients with cavitary MAC-PD (105 with the fibrocavitary type and 246 with the cavitary nodular bronchiectatic type), who had been treated with a >= 6-month macrolide-containing regimen at a tertiary referral center in South Korea, were retrospectively enrolled in this study. All-cause mortality during the follow-up period was analyzed based on culture conversion at the time of treatment completion. RESULTS: The cohort had a median treatment duration of 14.7 months (interquartile range [IQR], 13.4-16.8 months). Of the 351 patients, 69.8% (245 of 351) achieved culture conversion, and 30.2% (106 of 351) did not. The median follow-up was 4.4 years (IQR, 2.3-8.3 years) in patients with culture conversion and 3.1 years (IQR, 2.1-4.8 years) in those without. For the patients with and without culture conversion, all-cause mortality was 5.3% vs 35.8% (P < .001), and the 5-year cumulative mortality was 20.0% vs 38.4%, respectively. Cox analysis found that a lack of culture conversion was significantly associated with higher mortality (adjusted hazard ratio, 5.73; 95% CI, 2.86-11.50). Moreover, the 2-year landmark analysis revealed a distinct impact of treatment outcome on mortality. INTERPRETATION: The mortality rate of patients with cavitary MAC-PD who did not achieve culture conversion was significantly higher than that of those with culture conversion.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 31 条
  • [1] Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease
    Chae, Ganghee
    Park, Yea Eun
    Chong, Yong Pil
    Lee, Hyun Joo
    Shim, Tae Sun
    Jo, Kyung-Wook
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [2] Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease A Systematic Review
    Diel, Roland
    Nienhaus, Albert
    Ringshausen, Felix C.
    Richter, Elvira
    Welte, Tobias
    Rabe, Klaus F.
    Loddenkemper, Robert
    [J]. CHEST, 2018, 153 (04) : 888 - 921
  • [3] Mortality among patients with pulmonary non-tuberculous mycobacteria disease
    Fleshner, M.
    Olivier, K. N.
    Shaw, P. A.
    Adjemian, J.
    Strollo, S.
    Claypool, R. J.
    Folio, L.
    Zelazny, A.
    Holland, S. M.
    Prevots, D. R.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (05) : 582 - 587
  • [4] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
    Griffith, David E.
    Eagle, Gina
    Thomson, Rachel
    Aksamit, Timothy R.
    Hasegawa, Naoki
    Morimoto, Kozo
    Addrizzo-Harris, Doreen J.
    O'Donnell, Anne E.
    Marras, Theodore K.
    Flume, Patrick A.
    Loebinger, Michael R.
    Morgan, Lucy
    Codecasa, Luigi R.
    Hill, Adam T.
    Ruoss, Stephen J.
    Yim, Jae-Joon
    Ringshausen, Felix C.
    Field, Stephen K.
    Philley, Julie V.
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Coulter, Chris
    Nezamis, James
    Winthrop, Kevin L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
  • [5] Trends in the Nontuberculous Mycobacterial Disease Mortality Rate in Japan: A Nationwide Observational Study, 1997-2016
    Harada, Ko
    Hagiya, Hideharu
    Funahashi, Tomoko
    Koyama, Toshihiro
    Kano, Mitsunobu R.
    Otsuka, Fumio
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (02) : E321 - E326
  • [6] Prognostic Factors of 634 HIV-Negative Patients with Mycobacterium avium Complex Lung Disease
    Hayashi, Makoto
    Takayanagi, Noboru
    Kanauchi, Tetsu
    Miyahara, Yousuke
    Yanagisawa, Tsutomu
    Sugita, Yutaka
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 185 (05) : 575 - 583
  • [7] Impact of Time Between Diagnosis and Treatment for Nontuberculous Mycobacterial Pulmonary Disease on Culture Conversion and All-Cause Mortality
    Im, Yunjoo
    Hwang, Na Young
    Kim, Kyunga
    Kim, Hojoong
    Kwon, O. Jung
    Jhun, Byung Woo
    [J]. CHEST, 2022, 161 (05) : 1192 - 1200
  • [8] Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study
    Jhun, Byung Woo
    Moon, Seong Mi
    Jeon, Kyeongman
    Kwon, O. Jung
    Yoo, Heejin
    Carriere, Keumhee C.
    Huh, Hee Jae
    Lee, Nam Yong
    Shin, Sung Jae
    Daley, Charles L.
    Koh, Won-Jung
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (01)
  • [9] Jhun BW, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00011-18, 10.1128/aac.00011-18]
  • [10] Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity
    Kim, Bo-Guen
    Jhun, Byung Woo
    Kim, Hojoong
    Kwon, O. Jung
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)